Mark M. Awad
YOU?
Author Swipe
View article: Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis
Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis Open
Individuals with non-small-cell lung cancer (NSCLC) with metastases to the ipsilateral mediastinum or subcarinal lymph nodes (N2 disease) have poor long-term survival. This exploratory analysis from the randomized phase 3 CheckMate 77T stu…
View article: CRATER tumor niches facilitate CD8+ T cell engagement and correspond with immunotherapy success
CRATER tumor niches facilitate CD8+ T cell engagement and correspond with immunotherapy success Open
T cell-mediated tumor killing underlies immunotherapy success. Here, we used long-term in vivo imaging and high-resolution spatial transcriptomics of zebrafish endogenous melanoma, as well as multiplex imaging of human melanoma, to identif…
View article: Pan-cancer spatial characterization of key immune biomarkers in the tumor microenvironment
Pan-cancer spatial characterization of key immune biomarkers in the tumor microenvironment Open
Deciphering the composition and spatial organization of the tumor immune microenvironment (TIME) is key to understanding cancer progression and treatment response. Spatial biology techniques such as multiplex immunofluorescence (mIF) offer…
View article: Real‐world outcomes of neoadjuvant chemoimmunotherapy in patients with nonsmall cell lung cancer: Predictors of surgery, pathologic complete response, and event‐free survival
Real‐world outcomes of neoadjuvant chemoimmunotherapy in patients with nonsmall cell lung cancer: Predictors of surgery, pathologic complete response, and event‐free survival Open
Background Trials of neoadjuvant chemoimmunotherapy (chemoIO) have changed the standard of care for resectable nonsmall cell lung cancer (NSCLC). This study characterizes the outcomes of off‐trial patients who received treatment with neoad…
View article: Immunoprofiling at an Institutional Scale Reveals That High Numbers of Intratumoral CD8 <sup>+</sup> and PD-1 <sup>+</sup> Cells Predict Superior Patient Survival Across Major Cancer Types Independent of Major Risk Factors
Immunoprofiling at an Institutional Scale Reveals That High Numbers of Intratumoral CD8 <sup>+</sup> and PD-1 <sup>+</sup> Cells Predict Superior Patient Survival Across Major Cancer Types Independent of Major Risk Factors Open
PURPOSE Retrospective studies have found associations between the number of intratumoral immune cells and patient outcomes for specific cancers treated with targeted therapies. However, the clinical value of routinely quantifying intratumo…
View article: First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC
First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC Open
Purpose: First-line treatment options for MET exon 14 skipping–mutant metastatic non–small cell lung cancer vary because of differences in drug approvals and clinical experience. This study investigates factors influencing outcomes with fi…
View article: Distinct Clinicogenomic Features and Immunotherapy Associations in Pulmonary Sarcomatoid Carcinoma: A Multicenter Retrospective Study
Distinct Clinicogenomic Features and Immunotherapy Associations in Pulmonary Sarcomatoid Carcinoma: A Multicenter Retrospective Study Open
PSC exhibits improved outcomes to ICI relative to other therapies, potentially driven by high PD-L1 expression. Genomic analysis highlights a distinct genomic landscape of PSC when compared with LUAD.
View article: Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLC
Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLC Open
Immune checkpoint inhibitors (ICIs), either as monotherapy (ICI-Mono) or combined with chemotherapy (ICI-Chemo), improves survival in advanced non-small cell lung cancer (NSCLC). However, prospective guidance for choosing between these opt…
View article: Supplementary Figure 9 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Figure 9 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer Open
Supplementary Figure 9. Effect of ICI treatment duration on post-discontinuation survival outcomes using a restricted cubic spline model.
View article: Supplementary Figure 3 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Figure 3 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer Open
Supplementary Figure 3. Post-discontinuation survival outcomes according to age, histology, and best overall response.
View article: Supplementary Figure 1 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Figure 1 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer Open
Supplementary Figure 1. Study consort diagram.
View article: Data from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer
Data from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer Open
Purpose:Among patients with advanced non–small cell lung cancer (NSCLC) who discontinue immune checkpoint inhibitors (ICI) because of immune-related adverse events (irAE), post-discontinuation clinical outcomes and factors associated with …
View article: Supplementary Figure 4 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Figure 4 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer Open
Supplementary Figure 4. Post-discontinuation survival outcomes according to best overall response using a modified SD.
View article: Supplementary Tables 1-18 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Tables 1-18 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer Open
Supplementary Tables 1-18
View article: Supplementary Figure 5 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Figure 5 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer Open
Supplementary Figure 5. Post-discontinuation survival outcomes according to type of immune-related adverse events.
View article: Supplementary Figure 7 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Figure 7 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer Open
Supplementary Figure 7. Post-discontinuation survival outcomes according to PD-L1 TPS and TMB.
View article: Supplementary Figure 6 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Figure 6 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer Open
Supplementary Figure 6. Post-discontinuation survival outcomes according to type of therapy used for immune-related adverse events management.
View article: Supplementary Figure 2 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Figure 2 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer Open
Supplementary Figure 2. Timing of ICI discontinuation due to immune-related adverse events.
View article: Supplementary Figure 8 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Figure 8 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer Open
Supplementary Figure 8. Post-discontinuation survival outcomes according to ICI treatment duration before discontinuation.
View article: Data from Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with <i>MET</i> Rearrangements
Data from Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with <i>MET</i> Rearrangements Open
Oncogenic translocations involving the MET gene have been reported in several cancer types, but detailed clinicogenomic characterization of these cancers is not well defined. In addition, prospective clinical trials evaluating the antitumo…
View article: Supplementary Figures S1-S9 from Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with <i>MET</i> Rearrangements
Supplementary Figures S1-S9 from Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with <i>MET</i> Rearrangements Open
Supplementary Figure 1. Identification of MET rearrangement cases in the DFCI and GRCC cohorts. Supplementary Figure 2. Genomic features of MET rearrangements. Supplementary Figure 3. Oncoprint of likely oncogenic MET rearrangements and of…
View article: Supplementary Tables S1-S6 from Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with <i>MET</i> Rearrangements
Supplementary Tables S1-S6 from Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with <i>MET</i> Rearrangements Open
Supplementary Table 1. Clinical characteristics of patients with MET rearrangement-positive tumors in the DFCI/GRCC clinicopathologic cohort. Supplementary Table 2. Clinical characteristics of patients with MET fusion-positive tumors in th…
View article: Supplementary Methods from Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with <i>MET</i> Rearrangements
Supplementary Methods from Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with <i>MET</i> Rearrangements Open
Supplementary Methods
View article: Supplementary Appendix from Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with <i>MET</i> Rearrangements
Supplementary Appendix from Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with <i>MET</i> Rearrangements Open
Clinical trial protocol
View article: Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer
Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer Open
Purpose: Among patients with advanced non–small cell lung cancer (NSCLC) who discontinue immune checkpoint inhibitors (ICI) because of immune-related adverse events (irAE), post-discontinuation clinical outcomes and factors associated with…
View article: Supplementary Table S1 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
Supplementary Table S1 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial Open
Supplementary Table 1. Baseline and disease characteristics of patients.
View article: Supplementary Table S6 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
Supplementary Table S6 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial Open
Supplementary Table 6. Clinical characteristics of MAPK1/MAPK3-positive vs -negative patients in the Dana Farber Cancer Institute validation cohort.